Orlistat is a dietary supplement, or a drug often consumed to treat obesity. It is a gastrointestinal lipase inhibitor, which helps to block fat and prevents weight gain. Orlistat coupled with low-calorie and low-fat diet helps in weight loss. Orlistat is an effective drug that promotes weight loss.
Obesity is becoming a grave public health threat. The growing epidemic of obesity is a major factor driving the growth of the global orlistat market. Losing bodyweight consumes time and immense dedication, and hence, supplements such as orlistat help to achieve the result in much less time and to a great extent. Consumption of this drug, along with a low-fat diet and proper exercise results in achieving better results.
Hectic lifestyle, strains of modern-day living, and the pressure of juggling between work, family, social life are unavoidable. Hence, consumers often refrain from taking part in any physical activity and opts for an easier way to get rid of extra flesh. This is fueling the demand for orlistat and hence, driving the overall growth of the market.
The rise in disposable income is another major factor driving the growth of global orlistat. With the rise in disposable income, consumers are more likely to spend more on pills and supplements to curb fat.
Several side effects associated with weight loss drugs such as orlistat are expected to restrain the market growth. The consumption of orlistat often leads to fatty stools, defecation, loose stools, rectal pain, nausea, vomiting, liver failure, weakness, and loss of appetite, back, headache, skin rash, and others. Moreover, physical activity is fundamental in promoting weight control, reducing weight, and preventing obesity. The consumption of healthy food, along with a rise in participation in sports and other fitness activities, is also expected to hamper the demand for orlistat in the global market.
The global orlistat market can be segmented based on type, distribution channel, and region
In terms of type, the market can be classified into 60 mg and 120 mg. Based on the distribution channel, the orlistat market can be bifurcated into offline and online. The online segment can be sub-divided into a company-owned website and e-Commerce website. The offline segment can be sub-divided into organized stores and unorganized stores.
Based on the region, the global orlistat market can be divided into North America, South America, Asia Pacific, Middle East & Africa, and Europe. Furthermore, the regions are classified into countries such as the U.S., Canada, Germany, France, Italy, the U.K., GCC Countries, South Africa, China, India, Japan, Australia, and Brazil. North America is expected to account for a major share of the global orlistat market due to the prevalence of a high rate of obesity in North America.
The global orlistat market is expected to witness increased competition in the coming years, owing to the entry of new players in the global market. Manufacturers are focusing on product innovation to meet the increasing demand from consumers across the globe, thereby leading to the overall growth of the market.
Key players operating in the global orlistat market are HISUN Pharmaceuticals Co. Ltd., Sandoz Pharmaceuticals, National Company for Pharmaceutical Industry, Roche Holding AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Lunan Pharmaceutical Group Corporation Ltd., China Zhongshan Pharma Co. Ltd., ZEIN Pharmaceutical Co. Ltd., STADA–VN J.V. Co. Ltd., Hexal AG, Taj Pharmaceuticals Ltd., D.M. Pharma, and Kabir Life Sciences and Research Pvt. Ltd., among others
Orlistat Market, by Type
Orlistat Market, by Distribution Channel